ADRB3, ROCK2, and GEF Levels in Overactive Bladder Patients
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The aim of this study was to evaluate changes in levels of adrenergic receptor β3 (ADRB3), Rho-related kinase 2 (ROCK2), and guanine nucleotide exchange factor (GEF), which play key roles in the adrenergic and cholinergic pathways of contraction-relaxation harmony in voiding physiology, and to explore the relationship between these proteins and overactive bladder (OAB). Methods: This study included 60 idiopathic OAB patients and a healthy control group. A validated OAB-validated 8 questionnaire was completed by all participants. Serum levels of ADRB3, ROCK2, and GEF were examined with enzyme-linked immunosorbent assays. Patient and control groups were compared in terms of these levels, and receiver operating characteristic (ROC) curves were generated for all parameters. Results: The levels of ROCK2 were significantly elevated, but there were no correlations between the OAB symptom score and the serum levels of ROCK2, ADRB3, and GEF in OAB patients. In the ROC analysis, ROCK2 alone provided the strongest potential relationship (area under the curve=0.651) with 84.9% sensitivity. The ROCK2+GEF combination provided a satisfactory relationship (AUC=0.755). The AUC for the ADRB3+ROCK2+GEF combination was 0.752, with 64.2% sensitivity and 88.2% specificity. Conclusions: The study results suggest that alterations in serum ROCK2 levels and the use of this parameter in combination with ADRB3 and GEF levels can shed light on the pathophysiology of idiopathic OAB syndrome and provide a new perspective for treatment
Abstract
Purpose: The aim of this study was to evaluate changes in levels of adrenergic receptor β3 (ADRB3), Rho-related kinase 2 (ROCK2), and guanine nucleotide exchange factor (GEF), which play key roles in the adrenergic and cholinergic pathways of contraction-relaxation harmony in voiding physiology, and to explore the relationship between these proteins and overactive bladder (OAB). Methods: This study included 60 idiopathic OAB patients and a healthy control group. A validated OAB-validated 8 questionnaire was completed by all participants. Serum levels of ADRB3, ROCK2, and GEF were examined with enzyme-linked immunosorbent assays. Patient and control groups were compared in terms of these levels, and receiver operating characteristic (ROC) curves were generated for all parameters. Results: The levels of ROCK2 were significantly elevated, but there were no correlations between the OAB symptom score and the serum levels of ROCK2, ADRB3, and GEF in OAB patients. In the ROC analysis, ROCK2 alone provided the strongest potential relationship (area under the curve=0.651) with 84.9% sensitivity. The ROCK2+GEF combination provided a satisfactory relationship (AUC=0.755). The AUC for the ADRB3+ROCK2+GEF combination was 0.752, with 64.2% sensitivity and 88.2% specificity. Conclusions: The study results suggest that alterations in serum ROCK2 levels and the use of this parameter in combination with ADRB3 and GEF levels can shed light on the pathophysiology of idiopathic OAB syndrome and provide a new perspective for treatment
참고문헌 (19)
- Abrams P, "The standardisation of terminology of lower urinary tract function : report from the Standardisation Sub-committee of the International Continence Society", Neurourol Urodyn, 21, pp.167~178 (2002)
- Antunes-Lopes T, "Biomarkers in overactive bladder : a new objective and noninvasive tool", Adv Urol, 2011, pp.382431~ (2011)
- Meng E, "Pathophysiology of overactive bladder", Low Urin Tract Symptoms, 4(Suppl 1), pp.48~55 (2012)
- Yoshimura N, "Neurophysiology of lower urinary tract function and dysfunction", Rev Urol, 5(Suppl 8), pp.S3~S10 (2003)
- Puetz S, "Regulation of smooth muscle contraction by small GTPases", Physiology(Bethesda), 24, pp.342~356 (2009)
- Kimura K, "Regulation of myosin phosphatase by Rho and Rho-associated kinase(Rho-kinase)", Science, 273, pp.245~248 (1996)
- Amano M, "Phosphorylation and activation of myosin by Rho-associated kinase(Rho-kinase)", J Biol Chem, 271, pp.20246~20249 (1996)
- Sharma P, "ROCK-2-selective targeting and its therapeutic outcomes", Drug Discov Today, 25, pp.446~455 (2020)
- Ferreira CE, "The relationship between the Trp 64 Arg polymorphism of the beta 3-adrenoceptor gene and idiopathic overactive bladder", Am J Obstet Gynecol, 205, pp.82.e10~82.e14 (2011)
- Gormley EA, "Diagnosis and treatment of overactive bladder (nonneurogenic)in adults: AUA", SUFU guideline amendment, 2015, pp.193, 1572~1580
- Chapple CR, "Muscarinic receptor antagonists in the treatment of overactive bladder", Urology, 55(5A Suppl), pp.33~46 (2000)
- Huang CK, "Effectiveness of antimuscarinics and a beta-3 adrenoceptor agonist in patients with overactive bladder in a real-world setting", Sci Rep, 10, pp.11355~ (2020)
- Tarcan T, "OAB-V8 Asırı aktif mesane sorgulama formu validasyon calısmasi", Uroloji Bulteni, 21, pp.113~116 (2012)
- Fırat E, "Exploring biomarkers in the overactive bladder : Alterations in miRNA levels of a panel of genes in patients with OAB", Neurourol Urodyn, 38, pp.1571~1578 (2019)
- Fırat E, "Relation of ADRB3, GEF, ROCK2 gene polymorphisms to clinical findings in overactive bladder", World J Urol, 38, pp.2571~2575 (2020)
- Fei-Chi Chuang, "The Overactive Bladder Symptom Score, International Prostate Symptom Score–Storage Subscore, and Urgency Severity Score in Patients With Overactive Bladder and Hypersensitive Bladder: Which Scoring System is Best?", International Neurourology Journal, 22(2), pp.99~106 (2018), 대한배뇨장애요실금학회
- Arribillaga LC, "OAB score : a clinical model that predicts the probability of presenting overactive detrusor in the urodynamic study", Int Braz J Urol, 44, pp.348~354 (2018)
- 서윤석, "Potential Biomarkers for Diagnosis of Overactive Bladder Patients: Urinary Nerve Growth Factor, Prostaglandin E2, and Adenosine Triphosphate", International Neurourology Journal, 21(3), pp.171~177 (2017), 대한배뇨장애요실금학회
- Wang LW, "Urinary brain-derived neurotrophic factor : a potential biomarker for objective diagnosis of overactive bladder", Int Urol Nephrol, 46, pp.341~347 (2014)